ENANTA PHARMACEUTICALS INC - Common Stock (ENTA)

Q3 2017 13F Holders as of 9/30/2017

Type / Class: Equity / Common Stock
Shares outstanding: 21.5M
Number of holders: 119
Total 13F shares, excl. options: 12.8M
Shares change: +166K
Total reported value, excl. options: $597M
Value change: +$18.4M
Put/Call ratio: 0.3
Number of buys: 66
Number of sells: -45
Price: $46.80

Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) as of Q3 2017

137 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock as of Q3 2017.
ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12.8M shares of 21.5M outstanding shares and own 59.48% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.25M shares), Krensavage Asset Management, LLC (1.01M shares), FIRST MANHATTAN CO (947K shares), VANGUARD GROUP INC (838K shares), STATE STREET CORP (721K shares), Invesco Ltd. (703K shares), RENAISSANCE TECHNOLOGIES LLC (681K shares), DIMENSIONAL FUND ADVISORS LP (562K shares), FARALLON CAPITAL MANAGEMENT LLC (412K shares), and Stonepine Capital Management, LLC (390K shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.